In a straightforward effort to confront the silent epidemic of traumatic brain injuries (TBI), the University of Cincinnati has linked arms with a nationwide clinical trial. According to the University of Cincinnati's recent announcement, researchers are testing three FDA-approved drugs with the hope of pioneering more effective treatments for TBI recovery. The CDC estimates such injuries lead to over 586 hospitalizations and approximately 190 deaths per day in the U.S., carving out a critical need for medical innovation.
Acclaimed in the field of medicine, Dr. Laura Ngwenya leads the charge as the trial site's principal investigator. "These are drugs that are currently FDA-approved and used for different indications," according to the University of Cincinnati's news release. Not merely used for their initial purposes, atorvastatin calcium, minocycline hydrochloride, and candesartan cilexetil are the pharmaceuticals being evaluated for their potential to improve TBI outcomes. Standing behind an adaptive trial model, this allows for adjustments in real-time to the protocols, focusing more on the drugs exhibiting promise.
Patient recovery is no small feat, often involving follow-up blood draws, imaging, and numerous tests across a six-month span post-TBI. The trial is also set to explore biomarkers, not just to gauge recovery but to inform eligibility criteria, as per statements from the University. Engaging in such meticulous study, the researchers aim to correlate these biomarkers with patient recovery, honing in on the possibility of more personalized treatment options.
An expected cohort of 35 to 40 patients will partake in the trial at UC, with the broader study spanning 18 sites with an enrollment goal of around 672 patients. "Because the drugs selected for the study are already FDA-approved, successful completion of this trial will allow immediate use in clinical practice to improve outcomes for patients with TBI," Ngwenya noted in a hopeful undertone as reported by the University of Cincinnati's news article. The University of Cincinnati bills itself as a bastion of innovation and promises continued strides in the research frontier.
Those interested in this crucial medical exploration or seeking more detailed information can reach out at the provided contact number, 513-475-8001. The TRACK-TBI Network, under the umbrella of the University of California, San Francisco, sponsors the trial, casting a wide net of expertise across the study’s various sites. As the trial advances, its findings could represent a significant leap in clinical practice for those affected by the wide-reaching impact of TBI.
